US drug major Wyeth presented disappointing data from a Phase III trial comparing its osteoperosis treatment Viviant (bazedoxifene) with Eli Lilly's Evista (raloxifene) at the American Society of Bone and Mineral Research meeting in Montreal, Canada. The Wyeth drug failed to meet statistical significance. However, in a post-hoc subgroup analysis of subjects at the highest risk of fracture, Viviant 20mg significantly reduced the risk of non-vertebral fractures by 44% relative to Evista, but the Viviant 40mg reduction did not reach statistical significance.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze